These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10433170)

  • 1. Effects of gemfibrozil on lipid and hemostatic factors in CAPD patients.
    Lee MS; Kim SM; Kim SB; Lee SK; Park JS; Yang WS
    Perit Dial Int; 1999; 19(3):280-3. PubMed ID: 10433170
    [No Abstract]   [Full Text] [Related]  

  • 2. Hemostatic effects of omega-3 fatty acids in isolated hypertriglyceridemic patients treated with bezafibrate.
    Krysiak R; Okopien B
    Eur J Intern Med; 2012 Sep; 23(6):e168-9. PubMed ID: 22863446
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil.
    Elisaf MS; Dardamanis MA; Papagalanis ND; Siamopoulos KC
    Scand J Urol Nephrol; 1993; 27(1):101-8. PubMed ID: 8493456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
    Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ
    Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
    Akçiçek F; Ok E; Duman S; Kürsad S; Unsal A; Alev M; Atabay G; Basçi A
    Adv Perit Dial; 1996; 12():261-5. PubMed ID: 8865916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
    Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F
    Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of fenofibrate and gemfibrozil on plasma homocysteine.
    Chan NN; Chow FC
    Lancet; 2001 Nov; 358(9295):1811; author reply 1811-2. PubMed ID: 11734263
    [No Abstract]   [Full Text] [Related]  

  • 8. Safe use of gemfibrozil in uremic patients on continuous ambulatory peritoneal dialysis.
    Lucatello A; Sturani A; Di Nardo AM; Cocchi R; Fusaroli M
    Nephron; 1998; 78(3):338. PubMed ID: 9546699
    [No Abstract]   [Full Text] [Related]  

  • 9. Gemfibrozil lowers plasma lipids and increases polyunsaturated fatty acid content and oxidative susceptibility of lipoproteins in hypertriglyceridemia.
    Smith WG; Wang J; Dang AQ; Reeves C; Bibbs D; Faas FH
    Clin Chim Acta; 2002 Aug; 322(1-2):77-84. PubMed ID: 12104084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group.
    Avogaro A; Piliego T; Catapano A; Miola M; Tiengo A
    Acta Diabetol; 1999 Jun; 36(1-2):27-33. PubMed ID: 10436249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of severe hypertriglyceridemia lowers plasma viscosity.
    Stein JH; Rosenson RS
    Atherosclerosis; 1998 Apr; 137(2):401-5. PubMed ID: 9622283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients.
    Mussoni L; Mannucci L; Sirtori C; Pazzucconi F; Bonfardeci G; Cimminiello C; Notarbartolo A; Scafidi V; Bittolo Bon G; Alessandrini P; Nenci G; Parise P; Colombo L; Piliego T; Tremoli E
    Atherosclerosis; 2000 Feb; 148(2):397-406. PubMed ID: 10657576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Simvastatin and extrinsic coagulation pathway in peritoneally dialyzed patients].
    Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Myśliwiec M
    Pol Arch Med Wewn; 2002 Jun; 107(6):519-24. PubMed ID: 12371384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients.
    Hewitt RG; Shelton MJ; Esch LD
    AIDS; 1999 May; 13(7):868-9. PubMed ID: 10357393
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis.
    Malyszko J; Malyszko JS; Mysliwiec M
    Perit Dial Int; 2001; 21(2):158-65. PubMed ID: 11330560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemfibrozil in CAPD patients.
    De Vecchi A; Scalamogna A; Pini C; Castelnovo C; Colombini M; Lepore R
    Adv Perit Dial; 1991; 7():240-2. PubMed ID: 1680435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy.
    Lacko AG; Kudchodkar BJ; Loney WW; Clearfield MB; Weis S
    Clin Chem Lab Med; 1998 Jun; 36(6):389-92. PubMed ID: 9711427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of lipid abnormalities in patients on CAPD.
    Balaskas EV; Bamihas GI; Tourkantonis A
    Perit Dial Int; 1997; 17(3):308-9. PubMed ID: 9237296
    [No Abstract]   [Full Text] [Related]  

  • 19. Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations.
    Jeng CY; Sheu WH; Fuh MM; Shieh SM; Chen YD; Reaven GM
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2550-3. PubMed ID: 8675576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of fixed low-dose warfarin on hemostatic factors in continuous ambulatory peritoneal dialysis patients.
    Kim SB; Lee SK; Park JS; Chi HS; Hong CD; Yang WS
    Am J Kidney Dis; 2001 Feb; 37(2):343-7. PubMed ID: 11157376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.